CATALAYER NEWS
FDA Approves Arcutisâ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Source: BI Markets · 2026-06-29
Full article text is available in the Catalayer news terminal.
MORE FROM BI MARKETS
Direxion Daily Aerospace & Defense Bull 3X Shares declares quarterly distribution of $0.0118
2026-09-22
Direxion Daily Healthcare Bull 3X Shares declares quarterly distribution of $0.3152
2026-09-22
Direxion Auspice Broad Commodity Strategy ETF declares quarterly distribution of $0.2345
2026-09-22
Direxion Daily CSI 300 China A Share Bull 2X Shares declares quarterly distribution of $0.1109
2026-09-22
Kaplan Fox Reminds Investors of a Deadline for a Securities Fraud Class Action Lawsuit Against Blaize Holdings, Inc. (BZ
2026-09-22
RELATED ON CATALAYER
Related Topics
Biotech & FDA NewsRELATED MARKETS
Prediction Markets